February 18th, 2022
“Destroying Cancer with Boron and Neutrons” will be on NHK WORLD-JAPAN
Japan's public media organization NHK (Japan Broadcasting Corporation) will bro……
October 21st, 2021
Interview published on Science Japan, online magazine| Japan’s “Fifth Cancer Treatment,” BNCT, Finally Off the Ground
Here is a featured story on BNCT (Boron Neutron Capture Therapy) boron drug dev……
June 23rd, 2021
The phase II study of recurrent glioblastoma in Japan has published in “Neuro-Oncology Advances”
The title is “Accelerator-based BNCT for patients with recurrent glioblastoma: ……
December 9th, 2020
The phase II study of recurrent or locally advanced head and neck cancer in Japan has published in “Radiotherapy and Oncology”
The title is "Boron neutron capture therapy using cyclotron-based epithermal ne……
May 19th, 2020
STELLA PHARMA will launch Steboronine®, the World’s First BNCT Drug, on May 20, 2020
STELLA PHARMA CORPORATION (Head office: Chuoku, Osaka City; President: Tomoyuki……
March 25th, 2020
STELLA PHARMA Receives Marketing and Manufacturing Approval in Japan for “Steboronine® Intravenous Drip Bag 9000mg/300mL
STELLA PHARMA CORPORATION (Head office: Chuo-ku, Osaka City, President: Tomoyuk……
January 23rd, 2020
How to keep boron inside cells during radiotherapy: a simple novel approach to cancer treatment
Boron neutron capture therapy (BNCT) is a technique in which p‐boronophenylalan……
November 7th, 2019
“Commencement of Clinical Trial of Boron Neutron Capture Therapy (BNCT) for Malignant Melanoma and Angiosarcoma” issued
Cancer Intelligence Care Systems, Inc. (“CICS;” President: Tetsuya Furukawa; he……
October 15th, 2019
STELLA PHARMA CORPORATION has recently filed for approval to manufacture and sell a boron agent for BNCT
STELLA PHARMA CORPORATION (Head office: Chuo-ku, Osaka City; President: Tomoyuk……
